Literature DB >> 21412477

Introducing narrative practices in a locked, inpatient psychiatric unit.

Lewis Mehl-Madrona.   

Abstract

INTRODUCTION: Narrative approaches to psychotherapy are becoming more prevalent throughout the world. We wondered if a narrative-oriented psychotherapy group on a locked, inpatient unit, where most of the patients were present involuntarily, could be useful. The goal would be to help involuntary patients develop a coherent story about how they got to the hospital and what happened that led to their being admitted and link that to a story about what they would do after discharge that would prevent their returning to hospital in the next year.
METHODS: A daily, one-hour narrative group was implemented on one of three locked adult units in a psychiatric hospital. Quality-improvement procedures were already in place for assessing outcomes by unit using the BASIS-32 (32-item Behavior and Symptom Identification Scale). Unit outcomes were compared for the four quarters before the group was started and then four months after the group had been ongoing.
RESULTS: The unit on which the narrative group was implemented had a mean overall improvement in BASIS-32 scores of 2.8 units, compared with 1.0 unit for the other locked units combined. The results were statistically significant at the p < 0.0001 level. No differences were found between units for the four quarters prior to implementation of the intervention, and no other changes occurred during the quarter in which the group was conducted. Qualitative descriptions of the leaders' experiences are included in this report.
CONCLUSIONS: A daily, one-hour narrative group can make a difference in a locked inpatient unit, presumably by creating cognitive structure for patients in how to understand what has happened to them. Further research is indicated in a randomized, controlled-trial format.

Entities:  

Year:  2007        PMID: 21412477      PMCID: PMC3048434          DOI: 10.7812/TPP/07-026

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  10 in total

1.  Group treatment of auditory hallucinations. Exploratory study of effectiveness.

Authors:  T Wykes; A M Parr; S Landau
Journal:  Br J Psychiatry       Date:  1999-08       Impact factor: 9.319

2.  The Revised Behavior and Symptom Identification Scale (BASIS-R): reliability and validity.

Authors:  Susan V Eisen; Sharon-Lise Normand; Albert J Belanger; Avron Spiro; David Esch
Journal:  Med Care       Date:  2004-12       Impact factor: 2.983

3.  Negative explanation, restraint, and double description: a template for family therapy.

Authors:  M White
Journal:  Fam Process       Date:  1986-06

4.  Group therapy with schizophrenic patients: a short-term, homogeneous approach.

Authors:  N Kanas
Journal:  Int J Group Psychother       Date:  1991-01

5.  Effects of a coping-orientated group therapy for schizophrenia and schizoaffective patients: a pilot study.

Authors:  K Andres; M Pfammatter; F Garst; C Teschner; H D Brenner
Journal:  Acta Psychiatr Scand       Date:  2000-04       Impact factor: 6.392

6.  A cognitive-behavioural, group-based intervention for social anxiety in schizophrenia.

Authors:  S Halperin; P Nathan; P Drummond; D Castle
Journal:  Aust N Z J Psychiatry       Date:  2000-10       Impact factor: 5.744

7.  Therapy groups for schizophrenic patients on acute care units.

Authors:  N Kanas
Journal:  Hosp Community Psychiatry       Date:  1988-05

8.  Group treatment for substance abuse in schizophrenia.

Authors:  J Addington; N el-Guebaly
Journal:  Can J Psychiatry       Date:  1998-10       Impact factor: 4.356

9.  Group programmes for recovery from early psychosis.

Authors:  D J Albiston; S M Francey; S M Harrigan
Journal:  Br J Psychiatry Suppl       Date:  1998

10.  Auditory hallucinations in schizophrenia. Group experience in examining symptom management and behavioral strategies.

Authors:  R Buccheri; L Trygstad; N Kanas; B Waldron; G Dowling
Journal:  J Psychosoc Nurs Ment Health Serv       Date:  1996-02       Impact factor: 1.098

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.